Today we announced a major managed Medicare payer agreement and an expansion of the sales force for our FDA-approved #fibromyalgia treatment. Learn more: https://t.co/EjRAuRTkr8
#ChronicPain#Tonix
Tonix published Phase 1 clinical data for TNX-1500 in the peer-reviewed Journal of Clinical Immunology. Read more about our Phase 2 ready, investigational, anti-CD40L monoclonal antibody: https://t.co/bH6j5DnHvd
#Tonix#Immunology#KidneyTransplant
Thanks to @Lymealliance for hosting a symposium focused on the latest advances in Lyme last week! We appreciated the opportunity to sponsor the event and present on our investigational monoclonal antibody, TNX-4800.
#LymeDisease#LymeDiseaseAwarenessMonth
“Your tests are normal.” Words that people might hear, yet their lives are anything but.
In a new op-ed, Tonix CEO @SethLederman discusses why patient experiences aligned with the latest advances in medicine must remain central to care.
Read more: https://t.co/t8FCIAhNQ0
#Fibromyalgia #ChronicPain #Tonix
We’re on the ground at the @AAPAorg Conference! If you’re here, check out our 3 posters on the big screens and stop by our symposium and booth.
Also view the posters on our website: https://t.co/Heg9uGPJ7F
#AAPA26#Fibromyalgia#ChronicPain#Tonix
We look forward to our poster presentation at @ISPOR2026 on a retrospective U.S. real-world claims analysis characterizing patients with #fibromyalgia. Learn more, and see you there: https://t.co/Mo5lQXmIBO
#TNXP#Biotech#Fibromyalgia